Terminal deoxynucleotidyl transferase and application thereof

By optimizing the expression and catalytic site mutation of the terminal deoxynucleotide transferase at the bay crocodile, the problem of poor expression and thermal stability in enzymatic DNA synthesis is solved, and efficient enzymatic synthesis of oligonucleotides is achieved, and catalytic efficiency is improved. .

CN118910000APending Publication Date: 2024-11-08EAST CHINA UNIV OF SCI & TECH
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411020416.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing terminal deoxynucleotide transferases and their variants have shortcomings in expression levels, thermal stability and catalytic vitality, limiting the speed and length of enzymatic DNA synthesis.

Method used

Through database mining and amino acid mutations, the terminal deoxynucleotide transferase (CpTdT) and its functional fragments from the bay crocodile are optimized, and their expression level and thermal stability in the E. coli expression system are improved, and amino acid site mutations are performed. to enhance catalytic efficiency.

Benefits of technology

It has achieved efficient enzymatic synthesis of oligonucleotides, improved expression, thermal stability and catalytic efficiency, and is suitable for modern molecular biology and genetic engineering fields.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004967215180000141
    Figure BDA0004967215180000141
  • Figure BDA0004967215180000151
    Figure BDA0004967215180000151
  • Figure BDA0004967215180000152
    Figure BDA0004967215180000152
Patent Text Reader

Abstract

The invention relates to terminal deoxynucleotidyl transferase and application thereof, and particularly provides a polypeptide which has a sequence as shown in SEQ ID No.1 or a sequence having at least 75% sequence identity with the sequence as shown in SEQ ID No.1 or a fragment or a variant of the sequence as shown in SEQ ID No.1. The polypeptide disclosed by the invention has excellent heterologous protein expression level, strong thermal stability and efficient catalytic efficiency, and can be used for synthesizing nucleic acid molecules with determined or controllable sequences.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of enzymatic DNA synthesis, and specifically relates to mutants of terminal deoxynucleotidyl transferase (TdT) and its functional fragments. More particularly, the present invention relates to mutants suitable for incorporating modified nucleotides for synthesizing nucleic acid molecules with defined or controllable sequences. Background Art

[0002] Compared with traditional chemical synthesis methods, the polymerization mode and reaction conditions of enzymatic DNA synthesis are milder, can work in aqueous solution, can effectively reduce DNA damage and side reactions during the synthesis process, will not produce hazardous waste, and has the potential to continuously synthesize longer oligonucleotide fragments, which is expected to reduce the cost of DNA synthesis by 2 to 3 orders of magnitude. Therefore, enzymatic DNA synthesis is more environmentally friendly and has unparalleled potential in terms of synthesis speed, length, efficiency and cost compared to chemical synthesis.

[0003] Terminal deoxynucleotidyl transferase belongs to the polymerase X family and is one of the first DNA polymerases discovered in mammals. Its most remarkable property is that it can synthesize oligonucleotide chains with oligonucleotide chains of at least three nucleotides in length as primers without the need for a template chain, with high coupling efficiency and strong processivity. It is reported that terminal deoxynucleotidyl transferase can add multiple nucleotides within 1 second and extend single-stranded DNA to produce homopolymers up to 8000 nt. It has the potential to far exceed commercial phosphoramidite synthesis technology in terms of synthesis speed and length, so TdT has become an ideal candidate enzyme for enzymatic DNA synthesis.

[0004] As substrates for enzymatic DNA synthesis, deoxynucleoside triphosphates (RT-dNTPs) with reversible modification groups have larger volumes than natural nucleoside triphosphates (dNTPs). When they enter the catalytic pocket of the natural TdT enzyme, they are affected by steric hindrance and are not easily incorporated. The modification groups may also change the conformation of RT-dNTPs in the enzyme, thereby reducing the catalytic efficiency. This has become the biggest bottleneck for the practical application of TdT-based enzymatic DNA synthesis. Therefore, most researchers will improve the catalytic efficiency of RT-dNTPs through the exploration and molecular modification of TdT enzymes as the first step to achieve enzymatic DNA synthesis. For example, DNA Script has performed site-directed and combinatorial mutations near the blocking group of the MmTdT catalytic pocket to enlarge the catalytic substrate pocket or increase the flexibility of the enzyme structure to improve the catalytic efficiency of RT-dNTP. The efficiency of some mutants in catalyzing the incorporation of 3'-O-modified nucleoside triphosphates is more than twice that of the wild type. The Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, mutated and screened the amino acids around the substrate and obtained a TdT mutant that can reduce the probability of forming hydrogen bonds with the phosphate group of the substrate, making the conformation of RT-dNTP in the enzyme closer to natural nucleotides. The catalytic efficiency of the modified ZaTdT is about 67.6 times higher than that of the wild type.

[0005] Although enzymatic DNA synthesis has begun to surpass traditional chemical synthesis methods in terms of accuracy due to the efforts of many companies and research institutions, in order to further improve the speed and length of synthetic fragments of enzymatic DNA synthesis, in addition to optimizing the synthesis operation steps, the expression level, thermal stability and activity of the catalytic blocking group substrate of the key tool of this technology, terminal deoxynucleotidyl transferase (TdT), have become the main technical bottlenecks. The currently disclosed terminal deoxynucleotidyl transferase and its variants are not completely satisfactory, especially their poor heterologous expression level, poor thermal stability and low activity. Summary of the invention

[0006] The present invention provides a terminal deoxynucleotidyl transferase (TdT) and a functionalized mutant thereof having excellent expression, strong thermal stability and high catalytic efficiency. The present invention discloses a terminal deoxynucleotidyl transferase (TdT) derived from Crocodylus porosus and a functional fragment mutant thereof, and is used to synthesize oligonucleotides modified at the 3' position of the sugar ring.

[0007] In one aspect, the present invention provides a polypeptide, wherein:

[0008] (a) having the sequence shown in SEQ ID No. 1 or a sequence having at least 75% sequence identity thereto,

[0009] (b) a fragment of SEQ ID No. 1 having amino acids n-375, wherein n is a positive integer from 21 to 148, or a polypeptide having at least 75% sequence identity with the fragment, or

[0010] (c) is a variant of (a) or (b) having a mutation, wherein the mutation is a mutation at any one or more of the following positions: G192, G193, R196, K198, G201, H202, V253, D254, L256, G313, G316, R318, R325 and N338, or a polypeptide having at least 75% sequence identity with the variant and retaining the mutation,

[0011] (d) A polypeptide having terminal deoxynucleotidyl transferase activity formed by adding a tag sequence, a signal sequence or a secretion signal sequence to (a) or (b) or (c). The mutated amino acid numbering refers to SEQ ID NO: 1.

[0012] In one or more embodiments, n is 21, 41, 61, 81, 101, 121, 128, 141 or 148. That is, (b) is a fragment of SEQ ID No. 1 with 20, 40, 60, 80, 100, 120, 127, 140 or 147 amino acids removed from the N-terminus.

[0013] In one or more embodiments, (b) is as shown in SEQ ID NO:2.

[0014] In one or more embodiments, (c) is a variant of SEQ ID NO: 2 having said mutation.

[0015] In one or more embodiments, the mutation is selected from any one or more of the following groups:

[0016] (1) Any one of L256T, L256S, L256R, L256Q, L256P, L256N, L256I, L256W, L256E, L256M, L256K, L256H, L256G, L256F, L256D, L256C, and L256A,

[0017] (2) Any one of R318A, R318D, R318V, R318N, R318F, R318Q, R318W, R318I, R318E, R318G, R318C, R318H, R318T, R318K, R318L, R318M, R318P, R318S, and R318Y,

[0018] (3) any one of K198A, K198C, K198D, K198E, K198F, K198G, K198H, K198I, K198L, K198M, K198P, K198Q, K198R, K198S, K198T, K198V, K198W, K198Y, and K198N,

[0019] (4) any one of V253A, V253D, V253E, V253F, V253G, V253H, V253I, V253K, V253M, V253N, V253Q, V253R, V253S, V253T, V253W, V253Y, V253P, V253C, and V253L,

[0020] (5) G192A or G192H, (6) G193A, (7) D254A, (8) G201A, (9) H202A, (10) G313A, (11) G316A, (12) R325A and (13) any one of R196C, R196D, R196E, R196G, R196H, R196I, R196K, R196L, R196M, R196N, R196S, R196Q, R196V, R196W, R196Y, R196P, R196F, and R196T.

[0021] Another aspect of the present invention provides an isolated polynucleotide, the sequence of which comprises one or more selected from the group consisting of:

[0022] (a) a nucleotide sequence encoding a polypeptide described herein or a complementary sequence thereof,

[0023] (b) a nucleotide sequence having at least 80% (preferably at least 90%) identity with the sequence shown in (a), and

[0024] (c) The complementary sequence of (a) or (b).

[0025] Another aspect of the present invention provides a nucleic acid construct comprising the polynucleotide described herein.

[0026] In one or more embodiments, the nucleic acid construct is a vector. Preferably, the nucleic acid construct is an expression vector or a homologous recombination vector.

[0027] In one or more embodiments, the vector is a recombinant expression plasmid, which can be used for constitutive or inducible expression of the terminal deoxynucleotidyl transferase and its functional fragment mutant nucleic acid sequence of the present invention. Preferably, the plasmid is a pET plasmid, such as pET-28a(+).

[0028] Another aspect of the present invention provides a host cell, wherein:

[0029] (1) comprising, expressing or secreting a polypeptide or a variant thereof described herein,

[0030] (2) containing the polynucleotide described herein, or

[0031] (3) Containing the nucleic acid construct described herein.

[0032] In one or more embodiments, the host cell is a prokaryotic cell or a eukaryotic cell.

[0033] In one or more embodiments, the host cell is a prokaryotic cell, such as Escherichia coli, Bacillus or lactic acid bacteria. In one or more embodiments, the host cell is a eukaryotic cell, such as yeast or filamentous fungi. Preferably, the host cell is Escherichia coli.

[0034] In one or more embodiments, the host cell further expresses one or more proteins selected from the group consisting of: dnaK, dnaJ, grpE, groES, groEL, and tig.

[0035] In one or more embodiments, the host cell further expresses a protein selected from any one or more of the following groups:

[0036] (1)dnaK, dnaJ, grpE, groES, groEL,

[0037] (2) dnaK, dnaJ, grpE,

[0038] (3)groES, groEL,

[0039] (4)groES, groEL, tig

[0040] (5)tig.

[0041] Another aspect of the present invention provides a method for preparing the polypeptide described herein, wherein the method comprises the steps of: culturing the host cell described herein under conditions suitable for expressing the polypeptide described herein.

[0042] In one or more embodiments, the method comprises the steps of culturing the host cell of the present invention in a medium suitable for the growth of the host cell to obtain the polypeptide described herein.

[0043] In one or more embodiments, the method comprises:

[0044] (1) culturing the host cell of the present invention, isolating the host cell containing the recombinant terminal deoxynucleotidyl transferase,

[0045] (2) disrupting host cells containing the recombinant terminal deoxynucleotidyl transferase to obtain a crude enzyme solution,

[0046] (3) freeze-drying the pure enzyme solution containing the recombinant terminal deoxynucleotidyl transferase.

[0047] In one or more embodiments, the culture medium selected is TB, LB or autoinduction medium.

[0048] The present invention provides the use of the polypeptide described herein in catalyzing a terminal deoxynucleotide transfer reaction or synthesizing DNA. The reaction transfers a deoxyribonucleoside triphosphate to the 3' end of a DNA sequence (3'-OH of the 3' terminal nucleotide).

[0049] In one or more embodiments, the reaction catalyzes the formation of a phosphodiester bond between the 3'-OH of the last nucleotide of DNA and the α-phosphate group of a dNTP (deoxyribonucleoside triphosphate), while simultaneously breaking the phosphorus-oxygen bond of the dNTP to form pyrophosphate (PPi).

[0050] In one or more embodiments, the substrate for catalyzing the terminal deoxynucleotide transfer reaction comprises a deoxyribonucleoside triphosphate.

[0051] In one or more embodiments, the deoxyribonucleoside triphosphates have modifications, such as 3'-OCN3-modifications and / or 3'-ONH2-modifications.

[0052] The present invention provides a method for catalyzing terminal deoxynucleotide transfer reaction or synthesizing nucleic acid, comprising the steps of: contacting deoxyribonucleoside triphosphate with an oligodeoxynucleotide chain in the presence of the polypeptide described herein, wherein the oligodeoxynucleotide chain has a length of at least 3 nucleotides.

[0053] In one or more embodiments, the oligodeoxynucleotide is single-stranded or double-stranded.

[0054] In one or more embodiments, the deoxyribonucleoside triphosphates have modifications, such as 3'-OCN3-modifications and / or 3'-ONH2-modifications.

[0055] In one or more embodiments, the reaction system comprises: CoCl2, oligodeoxynucleotide chains, deoxyribonucleoside triphosphates, and the polypeptide described herein.

[0056] In one or more embodiments, the reaction conditions are 20-50°C (preferably 37°C) for at least 1 minute, and then optionally further comprise 70-99°C (preferably 95°C) for at least 1 minute. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1There are a total of 14 candidate enzymes including the probe enzyme obtained by database mining in the present invention.

[0058] Figure 2 The sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) map verifies the heterologous expression level of CpTdT improved by N-terminal truncation. Control: protein contained in the recombinant strain containing empty pET-28a (+); P: insoluble protein; S: soluble protein.

[0059] Figure 3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to verify the co-expression of the functional fragment of terminal deoxynucleotidyl transferase with five different molecular chaperone systems.

[0060] Figure 4 The catalytic efficiency of the beneficial mutants of N-140-CpTdT (SEQ ID No. 2) is compared with that of ZaTdT and its optimal mutant reported in the literature.

[0061] Figure 5 The figure shows the reaction process of N-140-CpTdT and its optimal mutant obtained by directed evolution within 6 hours.

[0062] Figure 6 The catalytic yield change of the mutant relative to SEQ ID No.2 in catalyzing the azidomethyl-modified substrate. DETAILED DESCRIPTION

[0063] The terminal deoxynucleotidyl transferases and their variants disclosed so far are not completely satisfactory, especially their heterologous expression levels are poor, their thermal stability is poor and their activity is low. The present invention selects a total of 14 candidate enzymes including probe sequences by means of database mining, combined with solubility prediction and molecular docking. After experimental verification, the CpTdT derived from the saltwater crocodile (Crocodylus porosus) was truncated at the N terminus to improve its expression level and thermal stability in the Escherichia coli expression system, which was increased by about 23 times and 9.5 times compared with the full-length protein expression level, and up to 171.8 mg of enzyme protein can be purified from each liter of culture medium. At 47°C, after CpTdT reacted for 2 minutes, its substrate conversion rate had almost no significant change, while N-140-CpTdT could continue to catalyze the reaction after 2-10 minutes of reaction. The inventors also mutated the enzyme with amino acids. Unlike previous studies, the mutation site of the mutant described in the present invention is closer to the base group of the substrate, rather than being limited to the amino acids near the blocking group or phosphate group. In addition, these mutants also exhibit higher synthesis efficiency, and the optimal mutant increases the specific activity of modified nucleotides by about 25.6 times compared to N-140-CpTdT. The terminal deoxynucleotidyl transferase and its functionalized mutants disclosed in the present invention have excellent expression levels, strong thermal stability and high catalytic efficiency, and can be used for efficient enzymatic synthesis of oligonucleotides, and are suitable for modern molecular biology, genetic engineering and synthetic biology. The TdT mutant of the present invention can enzymatically synthesize nucleic acid sequences in the absence of a template. More particularly, the present invention relates to mutants suitable for incorporating modified nucleotides for synthesizing nucleic acid molecules with a defined or controllable sequence.

[0064] As used herein, "isolated polypeptide" or "active polypeptide" means that the polypeptide is substantially free of other proteins, lipids, carbohydrates or other substances naturally associated therewith. Those skilled in the art can purify the polypeptide using standard protein purification techniques. Substantially pure polypeptides can produce a single major band on a non-reducing polyacrylamide gel. The purity of the polypeptide can also be further analyzed using amino acid sequences.

[0065] The active polypeptide of the present invention can be a recombinant polypeptide, a natural polypeptide, or a synthetic polypeptide. The polypeptide of the present invention can be a naturally purified product, or a chemically synthesized product, or produced from a prokaryotic or eukaryotic host (e.g., bacteria, yeast, plant) using recombinant technology. Depending on the host used in the recombinant production scheme, the polypeptide of the present invention can be glycosylated or non-glycosylated. The polypeptide of the present invention may also include or not include an initial methionine residue.

[0066] The present invention also includes fragments, derivatives and analogs of the polypeptide. As used herein, the terms "fragment", "derivative" and "analog" refer to polypeptides that substantially retain the same biological function or activity of the polypeptide.

[0067] The polypeptide fragments, derivatives or analogs of the present invention may be (i) polypeptides having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, and such substituted amino acid residues may or may not be encoded by the genetic code, or (ii) polypeptides having a substitution group in one or more amino acid residues, or (iii) polypeptides formed by fusion of a mature polypeptide with another compound (such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol), or (iv) polypeptides formed by fusion of an additional amino acid sequence to the polypeptide sequence (such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the polypeptide, or a fusion protein formed with an antigen IgG fragment). According to the teachings herein, these fragments, derivatives and analogs belong to the scope known to those skilled in the art.

[0068] The term "variant" or "mutant" refers to a peptide or polypeptide whose amino acid sequence is changed by insertion, deletion or substitution of one or more amino acids compared to a reference sequence but retains at least one biological activity. The mutant described in any embodiment herein includes an amino acid sequence having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97% sequence identity with a reference sequence (such as SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17 described herein) and retaining the biological activity of the reference sequence (such as as a glycosyltransferase). The sequence identity between two aligned sequences can be calculated using, for example, NCBI's BLASTp. Mutants also include amino acid sequences that have one or more mutations (insertions, deletions or substitutions) in the amino acid sequence of the reference sequence while still retaining the biological activity of the reference sequence. The multiple mutations generally refer to within 1-10, such as 1-8, 1-5 or 1-3. The substitution is preferably a conservative substitution. For example, in the art, when conservative substitutions are made with amino acids with similar or similar properties, the function of a protein or polypeptide is usually not changed. "Amino acids with similar or similar properties" include, for example, families of amino acid residues with similar side chains, including amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids with non-polar side chains (e.g., alanine, valine, leucine, isoleucine proline, phenylalanine, methionine, tryptophan), amino acids with β-branched side chains (e.g., threonine, valine, isoleucine) and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Therefore, replacing one or several sites in the polypeptide of the present invention with another amino acid residue from the same side chain class will not substantially affect its activity.

[0069] The present invention provides a polypeptide, wherein: (a) the polypeptide has a sequence as shown in SEQ ID No.1 or a sequence having at least 75% sequence identity thereto, and (b) is a fragment of SEQ ID No.1 having amino acids n-375, wherein n is a positive integer from 21 to 148 (e.g., 21, 41, 61, 81, 101, 121, 128, 141 or 148, i.e., SEQ ID No.1, wherein 20, 40, 60, 80, 100, 120, 127, 140 or 147 amino acids are removed from the N-terminus of the polypeptide), or a polypeptide having at least 75% sequence identity with the fragment, or (c) a variant of (a) or (b) having a mutation, wherein the mutation is selected from any one or more of the following sites: G192, G193, R196, K198, G201, H202, V253, D254, L256, G313, G316, R318, R325 and N338, or a polypeptide having at least 75% sequence identity with the variant and retaining the mutation, (d) a polypeptide having terminal deoxynucleotidyl transferase activity formed by adding a tag sequence, a signal sequence or a secretion signal sequence to (a) or (b) or (c). Herein, the amino acid number of the mutation refers to SEQ ID NO:1.

[0070] In one or more embodiments, the mutation is selected from any one or more of the following groups: (1) any one of L256T, L256S, L256R, L256Q, L256P, L256N, L256I, L256W, L256E, L256M, L256K, L256H, L256G, L256F, L256D, L256C, and L256A; (2) any one of R318A, R318D, R 318V, R318N, R318F, R318Q, R318W, R318I, R318E, R318G, R318C, R318H, R318T, R318K, R318L, R318M, R318P, R318S, R318Y, (3) K198A, K198C, K198D, K198E, K198F, K198G, K198H, K198 98I, K198L, K198M, K198P, K198Q, K198R, K198S, K198T, K198V, K198W, K198Y, K198N, (4) V253A, V253D, V253E, V253F, V253G, V253H, V253I, V253K, V253M, V253N, V253Q, V253R, V253 3S, V253T, V253W, V253Y, V253P, V253C, V253L, (5) G192A or G192H, (6) G193A, (7) D254A, (8) G201A, (9) H202A, (10) G313A, (11) G316A, (12) R325A and (13) R196C, R196D, R196E, R196G,

[0072] Any one of R196H, R196I, R196K, R196L, R196M, R196N, R196S, R196Q, R196V, R196W, R196Y, R196P, R196F, and R196T.

[0073] In one or more embodiments, the mutation is selected from any one of the following groups: (1) G192L and R198A, (2) G192A and K198A, (3) G192L and K198A, (4) G192H, R198A and N338H, (5) G192L, V253A and N338H, (6) G192L, V253A and R325I, (7) G192L, R198A and N338H, (8) R318A and N338H, (9) R31 8W and N338R, (10) R318A and N338R, (11) R318A and N338H, (12) G192H, R318A and N338H, (13) G192H, K198A and N338L, (14) G192H, K198A and N338R, (15) L256M, R325I and N338R, (16) L256M, R325Q and N338R, (17) V253E, L256M and N338R, ( 18) V253A, L256M, R325I and N338R, (19) V253E, L256M, R325Q and N338R, (20) G192L, V253E, L256M, R325Q and N338A, (21) G192L, V253E, L256M, R325Q and N338R, (22) G192L, V253D, L256M, R325Q and N338R, (23) G192L, V253E, L 256M, R325I and N338A, (24) G192L, K198A, L256M, R325Q and N338A, (25) G192L, K198A, L256M, R325Q and N338R, (26) G192L, K198A, L256M, R325I and N338A, (27) G192L, K198A, L256M, R325Q and N338A and (28) V253E, R325I and N338R.

[0074] Preferably, the mutation is selected from any one of the following groups: (1) G192A, (2) G193A, (3) R196G, (4) K198F, (5) G201A, (6) H202A, (7) V253L, (8) D254A, (9) G313A, (10) G316A, (11) R318A, (12) R325A, (13) R318A and N338H, (14) G192L and K198A, (15) G192L, R198A and N338H, (16) G192L, V253A and R3 25I, (17) V253E, L256M and N338R, (18) L256M, R325I and N338R, (19) V253E, L256M, R325Q and N338R, (20) G192L, V253E, L256M, R325Q and N338A, (21) G192L, K198A, L256M, R325Q and N338A, (22) G192L, K198A, L256M, R325Q and N338A and (23) V253E, R325I and N338R.

[0075] In one or more embodiments, the polypeptide of the present invention is as shown in SEQ ID NO:1 or SEQ ID NO:2 (the amino acid sequence shown in SEQ ID No.1 is 140 amino acids removed from the N-terminus), or a variant of SEQ ID NO:1 or SEQ ID NO:2 having the mutation. The polypeptide also includes variant forms and derivative polypeptides of the sequence of the polypeptide having the same function as the polypeptide shown. These variant forms include (but are not limited to): one or more (usually 1-50, preferably 1-30, more preferably 1-20, and most preferably 1-10) amino acid deletions, insertions and / or substitutions, and addition of one or several (usually within 20, preferably within 10, and more preferably within 5) amino acids at the C-terminus and / or N-terminus. For example, in the art, when amino acids with similar or similar properties are substituted, the function of the protein is usually not changed. For another example, adding one or several amino acids at the C-terminus and / or N-terminus usually does not change the function of the protein. The term also includes active fragments and active derivatives of the human polypeptide of the present invention. The present invention also provides analogs of the polypeptides. The difference between these analogs and the natural polypeptides of the present invention may be a difference in the amino acid sequence, or a difference in the form of modification that does not affect the sequence, or both. These polypeptides include natural or induced genetic variants. Induced variants can be obtained by various techniques, such as random mutagenesis by radiation or exposure to mutagens, or by site-directed mutagenesis or other known molecular biological techniques. Analogs also include analogs with residues different from natural L-amino acids (such as D-amino acids), and analogs with non-naturally occurring or synthetic amino acids (such as β, γ-amino acids). It should be understood that the polypeptides of the present invention are not limited to the representative polypeptides exemplified above.

[0076] The amino terminus or carboxyl terminus of the polypeptide of the present invention may also contain one or more polypeptide fragments as protein tags. Any suitable tag can be used in the present invention. For example, the tag can be FLAG, HA, HA1, c-Myc, Poly-His, Poly-Arg, Strep-TagII, AU1, EE, T7, 4A6, B, gE, and Ty1. These tags can be used to purify proteins.

[0077] In order to secrete the translated protein (such as secreted outside the cell), a signal peptide sequence may be added to the amino acid terminal of the polypeptide. The signal peptide may be cleaved off during the process of secretion of the polypeptide from the cell.

[0078] The present invention also provides an isolated polynucleotide, the sequence of which includes one or more selected from the following: (a) a nucleotide sequence encoding the polypeptide described herein or its complementary sequence, (b) a nucleotide sequence that is at least 80% (preferably at least 90%) identical to the sequence shown in (a).

[0079] The polynucleotide encoding the polypeptide described herein includes: a coding sequence encoding only the polypeptide; a coding sequence of the polypeptide and various additional coding sequences; a coding sequence of the polypeptide (and optional additional coding sequences) and non-coding sequences.

[0080] The polynucleotides of the present invention may be in the form of DNA or RNA. DNA forms include cDNA, genomic DNA or artificially synthesized DNA. DNA may be single-stranded or double-stranded. DNA may be a coding strand or a non-coding strand. The coding region sequence encoding the mature polypeptide may be a degenerate variant. As used herein, "degenerate variant" in the present invention refers to a nucleic acid sequence encoding a protein with the same amino acid sequence but a different nucleic acid sequence.

[0081] The present invention also relates to variants of the above-mentioned polynucleotides, which encode polypeptides or fragments, analogs and derivatives of polypeptides having the same amino acid sequence as the present invention. The variants of the polynucleotides may be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants and insertion variants. As known in the art, an allelic variant is an alternative form of a polynucleotide, which may be a substitution, deletion or insertion of one or more nucleotides, but will not substantially change the function of the polypeptide encoded by it.

[0082] The present invention also relates to polynucleotides that hybridize with the above sequences and have at least 50%, preferably at least 70%, more preferably at least 80%, 85%, 90%, 95% identity between the two sequences. The present invention particularly relates to polynucleotides that can hybridize with the polynucleotides of the present invention under stringent conditions (or stringent conditions). In the present invention, "stringent conditions" refer to: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) addition of denaturing agents during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C, etc.; or (3) hybridization occurs only when the identity between the two sequences is at least 90%, more preferably 95%. In addition, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the polypeptide described herein.

[0083] The present invention also relates to nucleic acid fragments that hybridize to the polynucleotides described herein. As used herein, a "nucleic acid fragment" has a length of at least 15 nucleotides, preferably at least 30 nucleotides, more preferably at least 50 nucleotides, and most preferably at least 100 nucleotides. Nucleic acid fragments can be used in nucleic acid amplification techniques (such as PCR) to identify and / or isolate polynucleotides encoding the polypeptides described herein.

[0084] The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and more preferably purified to homogeneity.

[0085] The full-length nucleotide sequence encoding the polypeptide of the present invention or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. For PCR amplification, primers can be designed based on the relevant nucleotide sequence disclosed in the present invention, especially the open reading frame sequence, and a commercially available cDNA library or a cDNA library prepared by conventional methods known to those skilled in the art is used as a template to amplify the relevant sequence. When the sequence is long, it is often necessary to perform two or more PCR amplifications, and then splice the fragments amplified in each time together in the correct order.

[0086] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the propagated host cells by conventional methods.

[0087] For example, the polypeptide described in this article is amplified by PCR, analyzed by 1% agarose nucleic acid electrophoresis, and then the position of the target band is determined by a gel imager, and the target band is recovered and purified using an agarose gel purification kit. Subsequently, the concentration of the recovered sample is determined by Nanodrop, and the recombinant plasmid is reconstructed by one-step cloning. Subsequently, transformation and screening are performed to obtain E. coli BL21 (DE3) strains of transformation-positive plasmids pET-28a (+) -CpTdT and pET-28a (+) -N-140-CpTdT, completing the construction of a heterologous expression system for CpTdT and its functional fragments.

[0088] In addition, artificial synthesis methods can also be used to synthesize relevant sequences, especially when the fragment length is short. Usually, by first synthesizing multiple small fragments and then connecting them, very long fragments of the sequence can be obtained. The DNA sequence encoding the protein of the present invention (or its fragment, or its derivative) can also be obtained completely by chemical synthesis. The DNA sequence can then be introduced into various existing DNA molecules (or such as vectors) and cells known in the art. In addition, mutations can also be introduced into the amino acid or nucleic acid sequence of the present invention by chemical synthesis.

[0089] The method of amplifying DNA / RNA using PCR technology is preferably used to obtain the gene of the present invention. In particular, when it is difficult to obtain full-length cDNA from a library, the RACE method (RACE-cDNA terminal rapid amplification method) can be preferably used. The primers used for PCR can be appropriately selected based on the sequence information of the present invention disclosed herein, and can be synthesized by conventional methods. The amplified DNA / RNA fragments can be separated and purified by conventional methods such as by gel electrophoresis.

[0090] The present invention also provides a nucleic acid construct comprising the polynucleotides described herein. It may also comprise one or more regulatory sequences operatively connected to these sequences or sequences required for homologous recombination of the genome (e.g., promoters, terminators, enhancers, insulators, etc.). The polynucleotides of the present invention can be manipulated in a variety of ways to ensure the expression of the polypeptide or protein. Before the nucleic acid construct is inserted into a vector, the nucleic acid construct may be manipulated according to the differences or requirements of the expression vector. The technology of using recombinant DNA methods to change polynucleotide sequences is known in the art.

[0091] In certain embodiments, the nucleic acid construct is a vector. The vector can be a cloning vector, an expression vector, or a gene knock-in vector. The polynucleotide of the present invention can be cloned into many types of vectors, for example, plasmids, phagemids, phage derivatives, animal viruses, and cosmids. Cloning vectors can be used to provide the coding sequence of the protein or polypeptide of the present invention. The expression vector can be provided to the cell in the form of a bacterial vector or a viral vector. Usually, the expression of the polynucleotide of the present invention is achieved by operably connecting the polynucleotide of the present invention to a promoter and incorporating the construct into the expression vector. The vector can be suitable for replication and integration of eukaryotic cells. Typical expression vectors include expression control sequences that can be used to regulate the expression of the desired nucleic acid sequence.

[0092] The vector can be constructed by conventional methods in the art, and the nucleic acid sequence encoding the polypeptide of the present invention or the nucleic acid sequence of the mutant gene is connected to various empty plasmids available on the market. The plasmid can be various plasmids conventional in the art, including but not limited to any expression vector in pET expression vector, pRSF expression vector, pUC expression vector or pBR expression vector. For different expression hosts, the preferred plasmid vector is different. The polypeptide gene can be operatively cloned downstream of the expression control sequence in the selected vector, so as to achieve constitutive or inducible expression of the polypeptide.

[0093] Preferably, as an example, for Escherichia coli hosts, pET-28a(+) plasmid is preferably used as a vector. The recombinant expression plasmid of the present invention can be prepared by the following method: by PCR amplification of the terminal deoxynucleotidyl transferase and its functional fragment gene, a recombinant expression plasmid pET-28a(+)-CpTdT / pET-28a(+)-NR-CpTdT containing the terminal deoxynucleotidyl transferase and its functional fragment encoding gene is obtained using a one-step cloning kit, wherein R can be any number.

[0094] The polypeptides described herein can be expressed or produced using the polynucleotide sequences of the present invention by conventional recombinant DNA techniques. In general, the following steps are involved: (1) transforming or transducing a suitable host cell with a polynucleotide (or variant) encoding the polypeptide of the present invention, or with an expression vector containing the polynucleotide; (2) culturing the host cell in a suitable culture medium; (3) isolating and purifying the protein from the culture medium or cells. The term "recombinant expression vector" refers to bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses or other vectors well known in the art. Any plasmid or vector can be used as long as it can replicate and be stable in the host.

[0095] The vector containing the above-mentioned appropriate DNA sequence and the appropriate promoter or control sequence can be used to transform the appropriate host cell to enable it to express the protein. The host cell can be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples include: Escherichia coli (e.g., E. coli BL21 (DE3)), Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; plant cells; insect cells of Drosophila S2 or Sf9; animal cells such as CHO, COS, 293 cells, or Bowes melanoma cells, etc. Those skilled in the art are aware of how to select appropriate vectors, promoters, enhancers and host cells. As an example, the recombinant expression plasmid pET-28a(+)-CpTdT / pET-28a(+)-NR-CpTdT (wherein R can be any number) described in the present invention is transformed into Escherichia coli BL21 (DE3) to obtain the recombinant expression transformant pET-28a(+)-CpTdT / pET-28a(+)-NR-CpTdT (wherein R can be any number).

[0096] Transformation of host cells with recombinant DNA can be carried out using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with the CaCl2 method, the steps used are well known in the art. Another method is to use MgCl2. If necessary, transformation can also be carried out using electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be selected: calcium phosphate coprecipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.

[0097] The obtained transformant can be cultured by conventional methods to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, the culture medium used in the culture can be selected from various conventional culture media. Culture is carried out under conditions suitable for the growth of the host cells. After the host cells grow to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.

[0098] The recombinant polypeptide in the above method can be expressed in the cell, on the cell membrane, or secreted outside the cell. If necessary, the recombinant protein can be separated and purified by various separation methods using its physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of these methods include but are not limited to: conventional renaturation treatment, treatment with a protein precipitant (salting out method), centrifugation, osmotic sterilization, ultra-treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography techniques and combinations of these methods.

[0099] The present invention also provides a method for preparing the polypeptide described herein, the method comprising the steps of: culturing the host cell described herein under conditions suitable for expressing the polypeptide described herein. In one or more embodiments, the method comprises: (1) culturing the host cell described herein, isolating the host cell containing the recombinant terminal deoxynucleotidyl transferase, (2) disrupting the host cell containing the recombinant terminal deoxynucleotidyl transferase to obtain a crude enzyme solution, and (3) freeze-drying the pure enzyme solution containing the recombinant terminal deoxynucleotidyl transferase.

[0100] The conditions and methods for culturing the recombinant expression host cell (or transformant) are conventional conditions and methods in the art, including the following steps: preparing a culture medium required for the growth of the recombinant expression host cell, culturing the recombinant expression host cell of the present invention, and obtaining a polypeptide catalyst. The culture medium can be selected from conventional culture media in the art, including but not limited to TB, LB or autoinduction culture media. For recombinant Escherichia coli, the preferred culture medium is TB culture medium: peptone 12g / L, yeast extract 24g / L, glycerol 5g / L, KH2PO4 2.31g / L, K2HPO4 12.54g / L. The preferred culture method is: after the recombinant Escherichia coli constructed by the above technical scheme is induced at 16°C for 20h, the culture solution is centrifuged, the cells are collected, the cells are crushed by an ultrasonic disruptor, and the supernatant is collected by centrifugation to obtain the crude enzyme solution of the terminal deoxynucleotidyl transferase. The crude enzyme solution is purified to obtain a pure enzyme solution. The protein purification experiment is completed using a 4mL Ni-affinity preloaded column. In one or more embodiments, the selected culture medium is TB, LB or autoinduction culture medium.

[0101] The present invention provides an application of the polypeptide (terminal deoxynucleotidyl transferase and its functional fragment mutant) of the present invention in catalyzing the synthesis of nucleic acid molecules by 3'-ONH2-dCTP, using a 30 μL reaction system: 0.25 mM CoCl2, 10 μM TdTstart (20 nt), 0.1 mM 3'-ONH2-dCTP, adding 2 μM TdT parent or mutant, reacting at 37°C, and heating at 95°C for 5 min to quench the reaction. The reaction process can be detected by conventional detection methods in the art, including but not limited to high performance liquid chromatography (HPLC) and TBE-urea PAGE; the preferred detection method is high performance liquid chromatography detection.

[0102] The present invention provides a method for catalyzing a terminal deoxynucleotide transfer reaction or synthesizing DNA, comprising the steps of: contacting a deoxyribonucleoside triphosphate with an oligodeoxynucleotide chain in the presence of a polypeptide described herein, wherein the oligodeoxynucleotide chain has a length of at least 3 nucleotides. The oligodeoxynucleotide is single-stranded or double-stranded. Specifically, the terminal deoxynucleotide transfer reaction or the synthesis of DNA is catalyzed in the following reaction system: 0.25 mM CoCl2, 10 μM TdTstart (20 nt), and 0.1 mM 3'-ONH2-dCTP.

[0103] The polypeptides described herein are suitable for incorporating modified nucleotides, such as 3'-OCN3-dNTP and / or 3'-ONH2-dNTP, 3'-O-2-cyanoethyl-dNTP, 3'-O-2-nitrobenzyl-dNTP, 3'-O,4,5-dimethoxy-2-nitrobenzyl-dNTP.

[0104] Example

[0105] Example 1, Database mining of terminal deoxynucleotidyl transferase

[0106] In order to discover TdT enzymes with higher catalytic efficiency, mouse-derived MmTdT and were used as probes to search for homologous sequences in the NCBI database. After removing redundancy, 227 sequences from different sources were selected to construct an evolutionary tree, and homology modeling was performed on the 227 candidate proteins. Subsequently, they were docked with four dNTP ligand molecules to evaluate the potential protein-ligand interface energy. According to the distribution of the evolutionary tree, candidate proteins with low and more evenly distributed predicted protein-ligand interface energies for the four substrates were selected on different branches to ensure that the selected proteins are diverse and have high catalytic ability and low preference for the four substrates, providing a good foundation for subsequent modification. A total of 14 sequences were selected (such as Figure 1 ) to conduct experimental characterization to screen out the ideal transformed parent.

[0107] Example 2: Construction of expression system of terminal deoxynucleotidyl transferase and functional fragments

[0108] The terminal deoxynucleotidyl transferase coding gene fragment was fully synthesized by GenScript, and EcoR I and Hind III restriction endonuclease sites were added to both ends of the coding region, and connected to the multiple cloning site of pET-28a(+). The recombinant plasmid synthesized and constructed by the company was transformed into E. coli BL21(DE3) competent cells to obtain the recombinant expression strain pET-28a(+)-TdT / BL21(DE3) containing the recombinant plasmid pET-28a(+)-TdT.

[0109] Using the artificially synthesized CpTdT gene as a template, PCR amplification was performed using the primers in Table 1 to obtain the terminal deoxynucleotidyl transferase fragment and the pET-28a(+) vector fragment. After agarose gel verification and gel recovery, the two fragments were cloned and connected in one step using the ClonExpress Ultra kit of Norvegicus to obtain the recombinant plasmid pET-28a(+)-NR-CpTdT (where R can be 20, 40, 60, 80, 100, 120, 127, 140 and 147).

[0110] The recombinant expression strain containing CpTdT and the functional fragment was induced to express, and the expression level of the CpTdT functional fragment was observed by SDS-PAGE. Figure 2 .

[0111] For protein purification, first use solution A to balance the Ni-affinity chromatography column. After the crushed supernatant is loaded onto the nickel column, 20% solution B is used to elute the impurities, and then the target protein TdT is eluted with solution B. The collected target protein is concentrated using a 10kDa ultrafiltration tube. When it is concentrated to 500μL, 5mL solution C is added to continue ultrafiltration and concentration. This is repeated 3-5 times to remove the imidazole in the enzyme solution and reduce the salt concentration to complete the replacement of the buffer. The solution A: 50mM KPB, 100mM NaCl, pH 6.8; solution B: 50mM KPB, 100mMNaCl, 300mM imidazole, pH 6.8; solution C: 50mM KPB, 100mM NaCl, pH 6.8. The concentration of the pure enzyme is measured by Nanodrop, and the extinction coefficient is calculated by Expasy tools to calculate the concentration and mass of the purified TdT, thereby characterizing the difference in the levels of different TdTs expressed by the same volume of culture medium and the same mass of bacteria, such as Figure 3 The pure enzyme solution was quickly frozen with liquid nitrogen and stored in a -80°C refrigerator.

[0112] Table 1

[0113]

[0114]

[0115] Table 2

[0116]

[0117]

[0118] Table 3

[0119]

[0120] Among them, steps 2-4 were repeated 30 times

[0121] Example 3, Optimization of expression of terminal deoxynucleotidyl transferase functional fragment

[0122] To further optimize the soluble expression of N-140-CpTdT with the highest expression level, we co-expressed it with five different molecular chaperone systems: dnaK-dnaJ-grpE-groES-groEL(pG-KJE8), groES-groEL(pGro7), dnaK-dnaJ-grpE(pKJE7), groES-groEL-tig(pG-Tf2) and tig(pTf16) to assist protein folding and enhance soluble expression. Figure 3 As shown, the soluble protein expression was optimal after co-expression with pGro7 plasmid.

[0123] Example 4, Construction, Expression and Purification of N-140-CpTdT Mutant

[0124] The recombinant plasmid pET-28a(+)-N-140-CpTdT was used as a template, and the primers in Table 4 were used to perform full plasmid PCR to perform site-directed mutagenesis on the nucleotide sequence encoded as shown in SEQ ID No. 2 in the sequence table. The PCR reaction system is shown in Table 5, and the reaction conditions are shown in Table 3. After 2 μL of PCR product was verified to be correct by 1% agarose gel electrophoresis, the DNA template was digested with restriction endonuclease Dpn I, the enzyme digestion reaction temperature was 37°C, the reaction time was 2 h, and then the enzyme digestion product was transformed into E. coli BL21 (DE3) competent cells. Spread LB solid plates (peptone 10g / L, yeast extract 5g / L, sodium chloride 10g / L, agar powder 15g / L) containing 50μg / mL kanamycin, culture at 37°C for 12h, pick 1-3 transformants and transfer them to LB liquid culture medium (containing 50μg / mL kanamycin), culture at 37°C, 200rpm for 8-12h, and send the bacterial solution to Beijing Qingke Biotechnology Co., Ltd. for sequencing to verify the successful mutation. The expression and purification of the recombinant plasmid are the same as in Example 2. Exemplary primer sequences for each site are shown in Table 4, and primers for other mutation types can be constructed with reference to Table 4 and amino acid codons known in the art. The mutation type obtained is expressed in the form of "140-mutation site", as shown in Table 6.

[0125] Table 4

[0126]

[0127] Table 5

[0128]

[0129] Example 5, Determination of the catalytic efficiency of TdT

[0130] When evaluating different TdTs for enzymatic DNA synthesis, 3'-ONH2-dNTP was selected as the target substrate. A 30 μL reaction system was selected: 0.25 mM CoCl2, 10 μM TdTstart (CGCTTGCACAGGTGCTTCAT, SEQ ID NO: 63) (20 nt), 0.1 mM 3'-ONH2-dCTP, 2 μM TdT parent (SEQ ID NO: 2) or mutant was added, reacted at 37°C for 60 min, and heated at 95°C for 5 min to quench the reaction.

[0131] Take 20 μL of the reaction solution and mix it with 80 μL of 100 mM TEAA (triethylamine acetic acid) buffer at pH 7.0. Inject 10 μL each time, the mobile phase ratio is ACN:TEAA=1:9, the flow rate is 0.5 mL / min, the detection wavelength is 260 nm, and the analysis time is 25 min.

[0132] The multiple of the mutant's specific activity improvement can be calculated by comparing the peak area of ​​the product catalyzed by the mutant with the peak area of ​​the product catalyzed by SEQ ID No. 2. The calculation results are shown in Table 6.

[0133] Table 6

[0134]

[0135]

[0136]

[0137] In order to evaluate the changes in catalytic efficiency between the mutants obtained in this study and the enzymes reported in the literature, we used TBE-UreaPAGE technology to compare the composition of the 20nt substrate and 21nt product of the beneficial mutants obtained in this study and the ZaTdT and its optimal mutant ZaTdTR335L-K337G reported in the literature after 5 minutes of reaction at 37°C. Figure 4 As shown, the higher the band intensity ratio of the 21nt product to the 20nt substrate, the higher the catalytic efficiency of the enzyme in the same time. The catalytic efficiency of G192L / V253E / L256M / R325I / N338A is higher than that of the best mutant ZaTdTR335L-K337G in the literature.

[0138] Example 6: Terminal deoxynucleotidyl transferase and its functional fragment mutants for enzymatic synthesis of DNA

[0139] The catalyst with terminal deoxynucleotidyl transferase activity obtained according to Example 1-3 was used, and the mutant G192L / V253E / L256M / R325I / N338A described in SEQ ID NO.2 and Example 5 was used to synthesize the sequence 5'-CGCTTGCACAGGTGCTTCAT-3' after the single-stranded DNA of the sequence 5'-CGCTTGCACAGGTGCTTCAT-3' (combined with HPLC detection). A 30 μL reaction system was used: 0.25 mM CoCl2, 10 μM TdTstart (SEQ ID NO: 63, 20 nt), 0.1 mM 3'-ONH2-dCTP, 2 μM TdT was added, and the reaction progress within 6 h at 37°C was as follows. Figure 5 shown.

[0140] Example 7, TdT catalyzes the modification of substrates with azidomethyl groups

[0141] Evaluate different TdT mutants to catalyze azidomethyl-modified substrates to synthesize DNA. Choose to use a 30μL reaction system: 0.25mM CoCl2, 10μM TdTstart (20nt), 0.1mM 3'-OCN3-dCTP or 3'-OCN3-dATP (the types of substrates available for purchase in the experiment are limited, and in fact all four azidomethyl-modified dNTPs can be used as substrates), add 2μM TdT parent (SEQ ID NO: 2) or mutant, react at 37°C for 60min, and heat at 95°C for 5min to quench the reaction. The activity increase fold relative to SEQ ID No.2 is calculated by the peak area of ​​the product catalyzed by the mutant and the peak area of ​​the product catalyzed by SEQ ID No.2. The calculation results are shown in Figure 6 As shown, the catalytic yields of several mutants were improved relative to SEQ ID No. 2.

[0142] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application is intended to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the disclosed scope of this application. Applications of some of the basic features may be made within the scope of the following appended claims.

Claims

1. A polypeptide, wherein: (a) having the sequence shown in SEQ ID No. 1 or a sequence having at least 75% sequence identity thereto, (b) a fragment of SEQ ID No. 1 having amino acids n-375, wherein n is a positive integer from 21 to 148, or a polypeptide having at least 75% sequence identity with the fragment, or (c) is a variant of (a) or (b) having a mutation, wherein the mutation is a mutation at any one or more of the following positions: G192, G193, R196, K198, G201, H202, V253, D254, L256, G313, G316, R318, R325 and N338, or a polypeptide having at least 75% sequence identity with the variant and retaining the mutation, (d) A polypeptide having terminal deoxynucleotidyl transferase activity obtained by adding a tag sequence, a signal sequence or a secretion signal sequence to (a) or (b) or (c).

2. The polypeptide according to claim 1, characterized in that n is 21, 41, 61, 81, 101, 121, 128, 141 or 148.

3. The polypeptide according to claim 1, characterized in that The mutation is selected from any one or more of the following groups: (1) Any one of L256T, L256S, L256R, L256Q, L256P, L256N, L256I, L256W, L256E, L256M, L256K, L256H, L256G, L256F, L256D, L256C, and L256A, (2) Any one of R318A, R318D, R318V, R318N, R318F, R318Q, R318W, R318I, R318E, R318G, R318C, R318H, R318T, R318K, R318L, R318M, R318P, R318S, and R318Y, (3) any one of K198A, K198C, K198D, K198E, K198F, K198G, K198H, K198I, K198L, K198M, K198P, K198Q, K198R, K198S, K198T, K198V, K198W, K198Y, and K198N, (4) any one of V253A, V253D, V253E, V253F, V253G, V253H, V253I, V253K, V253M, V253N, V253Q, V253R, V253S, V253T, V253W, V253Y, V253P, V253C, and V253L, (5) G192A or G192H, (6) G193A, (7) D254A, (8) G201A, (9) H202A, (10) G313A, (11) G316A, (12) R325A and (13) any one of R196C, R196D, R196E, R196G, R196H, R196I, R196K, R196L, R196M, R196N, R196S, R196Q, R196V, R196W, R196Y, R196P, R196F, and R196T.

4. The polypeptide according to claim 1, characterized in that The mutation is selected from any one of the following groups: (1) G192L and R198A, (2) G192A and K198A, (3) G192L and K198A, (4) G192H, R198A and N338H, (5) G192L, V253A and N338H, (6) G192L, V253A and R325I, (7) G192L, R198A and N338H, (8) R318A and N338H, (9) R318W and N338R, (10) R318A and N338R, (11) R318A and N338H, (12) G192H, R318A and N338H, (13) G192H, K198A and N338L, (14) G192H, K198A and N338R, (15) L256M, R325I and N338R, (16) L256M, R325Q and N338R, (17) V253E, L256M and N338R, (18) V253A, L25 6M, R325I and N338R, (19) V253E, L256M, R325Q and N338R, (20) G192L, V253E, L256M, R325Q and N338A, (21) G192L, V253E, L256M, R325Q and N338R, (22) G192L, V253D, L256M, R325Q and N338R, (23) G192L, V253E, L256M, R 325I and N338A, (24) G192L, K198A, L256M, R325Q and N338A, (25) G192L, K198A, L256M, R325Q and N338R, (26) G192L, K198A, L256M, R325I and N338A, (27) G192L, K198A, L256M, R325Q and N338A and (28) V253E, R325I and N338R.

5. An isolated polynucleotide, the sequence of which comprises one or more selected from the group consisting of: (a) a nucleotide sequence encoding the polypeptide according to any one of claims 1 to 4 or a complementary sequence thereof, and (b) a nucleotide sequence that is at least 80% identical to the sequence shown in (a), (c) The complementary sequence of (a) or (b).

6. A nucleic acid construct comprising the polynucleotide according to claim 5, Preferably, the nucleic acid construct is a vector.

7. A host cell, wherein: (1) comprising, expressing or secreting the polypeptide or variant thereof according to any one of claims 1 to 4, (2) comprising the polynucleotide according to claim 5, or (3) comprising the nucleic acid construct according to claim 6, Preferably, the host cell is a prokaryotic cell or a eukaryotic cell.

8. A method for preparing the polypeptide according to any one of claims 1 to 4, comprising the step of culturing the host cell according to claim 7 under conditions suitable for expressing the polypeptide.

9. Use of the polypeptide according to claim 1 in catalyzing terminal deoxynucleotide transfer reaction or synthesizing DNA, The reaction transfers deoxynucleotides to the 3' end of the DNA sequence, and / or The substrate for catalyzing the terminal deoxynucleotide transfer reaction includes deoxynucleotides, and / or The deoxynucleotides have modifications, such as 3'-OCN3-modification and / or 3'-ONH2-modification.

10. A method for catalyzing a terminal deoxynucleotide transfer reaction or synthesizing DNA, comprising the steps of: contacting a deoxynucleotide with an oligodeoxynucleotide chain in the presence of a polypeptide according to any one of claims 1 to 4, wherein the oligodeoxynucleotide chain has a length of at least 3 nucleotides, Preferably, The oligodeoxynucleotide is single-stranded or double-stranded, and / or The deoxynucleotides have modifications, such as 3'-OCN3-modification and / or 3'-ONH2-modification, and / or The reaction system comprises: CoCl2, oligodeoxynucleotide chains, deoxynucleotides, the polypeptide, and / or The reaction conditions are 20-50° C. for at least 1 minute, and then optionally further comprise 70-99° C. for at least 1 minute.

Citation Information

Cited By

  • Controllable synthesized single-stranded DNA terminal deoxynucleotidyl transferase mutant and application thereof

    CN119570761A

  • Terminal deoxyribonucleotide transferase variant, nucleic acid and kit

    CN119662594A

  • Culture medium for fermenting terminal deoxynucleotidyl transferase and application of culture medium

    CN120699876A